Research Article
The Prognostic Role of SIRT1-Autophagy Axis in Gastric Cancer
Table 3
Univariate Cox proportional hazards regression analysis of GC patients’ clinicopathological characteristics and OS and RFS.
| | Characteristics | N | OS | RFS | | HR (95% CI) | p | HR (95% CI) | p |
| | BMI (24 versus <24) | 21 versus 75 | 0.543 (0.274–1.072) | 0.079 | 0.553 (0.280–1.094) | 0.089 | | Tumor size (5 versus ≤5cm) | 30 versus 66 | 1.745 (1.025–2.969) | | 1.710 (1.005–2.911) | | | Lauren classification (Diffuse versus Intestinal) | 36 versus 60 | 1.373 (0.817–2.307) | 0.231 | 1.360 (0.809–2.286) | 0.245 | | Histologic grade (PD versus WD and MD) | 69 versus 27 | 2.673 (1.383–5.167) | | 2.663 (1.377–5.150) | | | LN metastasis (Positive versus Negative) | 72 versus 24 | 49.924 (6.792–366.946) | < | 46.792 (6.380–343.202) | < | | Tumor invasion (AGC versus EGC) | 87 versus 9 | 27.242 (1.198–619.630) | | 26.825 (1.152–624.503) | | | TNM stage (III and IV versus I and II) | 72 versus 24 | 37.857 (5.199–275.640) | < | 36.784 (5.056–267.642) | < | | VCE (Positive versus Negative) | 39 versus 57 | 1.551 (0.927–2.596) | 0.095 | 1.540 (0.920–2.577) | 0.100 | | SIRT1 expression (High versus Low) | 53 versus 43 | 5.163 (2.820–9.452) | < | 4.949 (2.706–9.052) | < | | Beclin1 expression (High versus Low) | 57 versus 39 | 5.994 (3.055–11.763) | < | 6.019 (3.069–11.804) | < | | Beclin-1/SIRT1 expression (Low/High versus Low/Low) | 9 versus 30 | 2.926 (0.846–10.117) | 0.090 | 2.911 (0.841–10.081) | 0.092 | | Beclin-1/SIRT1 expression (High/Low versus Low/Low) | 13 versus 30 | 1.980 (1.183–3.314) | | 2.006 (1.198–3.358) | | | Beclin-1/SIRT1 expression (High/High versus Low/Low) | 44 versus 30 | 2.297 (1.718–3.071) | < | 2.266 (1.697–3.025) | < | | Beclin-1/SIRT1 expression (High/Low versus Low/High) | 13 versus 9 | 1.280 (0.383–4.282) | 0.688 | 1.416 (0.424–4.723) | 0.572 | | Beclin-1/SIRT1 expression (High/High versus Low/High) | 44 versus 9 | 1.870 (1.110–3.149) | | 1.889 (1.123–3.178) | | | Beclin-1/SIRT1 expression (High/High versus High/Low) | 44 versus 13 | 3.051 (1.409–6.604) | | 2.853 (1.322–6.154) | |
|
|
BMI, body mass index; LN metastasis, lymph node metastasis; TNM stage, tumor node metastasis stage; VCE, vascular cancer embolus; WD, well differentiation; MD, middle differentiation; PD, poor differentiation; EGC, early gastric cancer; AGC, advantage gastric cancer; N, number of patients; OS, overall survival; RFS, relapse-free survival; HR, hazard ratio; CI, confidence interval; ; .
|
